Table 2 Histopathological and clinical parameters of patients subjected to paired analysis of galectin-1 and galectin-3 expression in tumors vs. adjacent normal kidney tissue
From: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
| Patients for paired analysis | No. | % |
|---|---|---|
| Total | 75 | 100% |
| Patients | ||
| Age (mean; ±SD) | 67 (11.8) | |
| Male | 46 | 61.3% |
| Female | 29 | 38.7% |
| Histology | ||
| Clear cell | 58 | 77.3% |
| Papillary | 12 | 16% |
| Chromophobe | 4 | 5.3% |
| Other/notclassified | 1 | 1.3% |
| Stage | ||
| NA | 3 | 4% |
| pT1 | 4 | 5.3% |
| pT1a | 24 | 32% |
| pT1b | 14 | 18.7% |
| pT2 | 4 | 5.3% |
| pT3 | 1 | 1.3% |
| pT3a | 6 | 8% |
| pT3b | 19 | 25.3% |
| pT4 | 0 | 0% |
| Grade | ||
| G1 | 9 | 12% |
| G1-2 | 11 | 14.7% |
| G2 | 40 | 53.3% |
| G2-3 | 6 | 8% |
| G3 | 9 | 12% |
| LN metastasis* | 7 | 9.3% |
| Visceral metastasis* | 19 | 25.3% |
| locally advanced/metastatic | ||
| disease (pT3>4 and/or N/M+) | 36 | 48% |